Quick answers
- What is Armodafinil used for?
- The FDA-approved label (Nuvigil, Cephalon, LLC, December 31, 2022) says: “NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Limitations of Use In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Armodafinil have a boxed warning?
- No. None of the 14 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Armodafinil?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Armodafinil been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Armodafinil?
- 13 companies list prescription products of Armodafinil in the FDA NDC Directory, including Golden State Medical Supply, Inc., Natco Pharma USA LLC and Sandoz Inc.
What Armodafinil is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Limitations of Use In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. …
— FDA label: Nuvigil, Cephalon, LLC, effective December 31, 2022. Read the full label on DailyMed →
The FDA has 14 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 14 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 37 in the FDA NDC Directory |
| Brand names | Nuvigil |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| armodafinil 150 mg tablet | Generic | $0.8011 per tablet |
| armodafinil 150 mg tablet | Brand: Nuvigil | $34.75 per tablet |
| armodafinil 200 mg tablet | Generic | $0.7925 per tablet |
| armodafinil 200 mg tablet | Brand: Nuvigil | $35.06 per tablet |
| armodafinil 250 mg tablet | Generic | $0.8751 per tablet |
| armodafinil 250 mg tablet | Brand: Nuvigil | $34.70 per tablet |
| armodafinil 50 mg tablet | Generic | $0.2960 per tablet |
NADAC list of November 4, 2026; these prices took effect between November 19, 2025 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Golden State Medical Supply, Inc.4 products
- Natco Pharma USA LLC4 products
- Sandoz Inc4 products
- Apotex Corp.4 products
- Aurobindo Pharma Limited4 products
- Mylan Pharmaceuticals Inc.3 products
- Teva Pharmaceuticals USA, Inc.3 products
- Direct_Rx3 products
- Bryant Ranch Prepack3 products
- Preferred Pharmaceuticals Inc.2 products
- DirectRx1 product
- Quality Care Products, LLC1 product
- Cephalon, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021875 NUVIGIL | Nuvo Pharms | June 15, 2007 | 12, latest February 7, 2017 2017: Labeling · 2015: Labeling · 2015: Manufacturing (CMC) |
Generic approvals (3)
- ANDA200043Mylan Pharms Inc · June 1, 2012
- ANDA202768Natco Pharma Ltd · November 28, 2016
- ANDA206069Aurobindo Pharma Ltd · March 6, 2018
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Nuvigil, Cephalon, LLC, effective December 31, 2022; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →